Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by NEALE, M. L.
Right arrow Articles by MATTHEWS, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by NEALE, M. L.
Right arrow Articles by MATTHEWS, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 British Society for Rheumatology

research-article

TUMOUR NECROSIS FACTOR ACTIVITY IN JOINT FLUIDS FROM RHEUMATOID ARTHRITIS PATIENTS

M. L. NEALE1, B. D. WILLIAMS* and N. MATTHEWS

Departments of Medical Microbiology Heath Park, Cardiff CF4 4XN
*Medicine, University of Wales College of Medicine Heath Park, Cardiff CF4 4XN

Correspondence to: 1Correspondence to Dr. Neale.

Although tumour necrosis factor (TNF) was first studied as an anti-cancer agent it is now recognized as a potent mediator of inflammation and could potentially play a role in rheumatoid arthritis. In this study TNF activity has been sought in fluids from arthritic joints. TNF was assayed by a well established bioassay which depends upon cytolysis of particular tumour cell lines and which has a limit of detection of c. 25 pg/ ml. Of the 92 joint fluids tested (70 rheumatoid and 22 others) only three had demonstrable TNF activity. Despite this, joint fluid cells from all 14 patients tested (12 rheumatoid and two others) had the ability to synthesize TNF on stimulation in vitro. Subsequently it was shown that joint fluids contain a macro-molecule which inhibits TNF activity in cytolytic assays and which may mask low levels of TNF activity in joint fluids.

KEY WORDS: Rheumatoid arthritis, Tumour necrosis factor, Cytokines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
E. MUSACCHIO, C. VALVASON, C. BOTSIOS, F. OSTUNI, A. FURLAN, R. RAMONDA, V. MODESTI, L. SARTORI, and L. PUNZI
The Tumor Necrosis Factor-{alpha}-blocking Agent Infliximab Inhibits Interleukin 1ss (IL-1ss) and IL-6 Gene Expression in Human Osteoblastic Cells
J Rheumatol, August 1, 2009; 36(8): 1575 - 1579.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. K. Kiemer, T. Hartung, and A. M. Vollmar
cGMP-Mediated Inhibition of TNF-{alpha} Production by the Atrial Natriuretic Peptide in Murine Macrophages
J. Immunol., July 1, 2000; 165(1): 175 - 181.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Myokai, S. Takashiba, R. Lebo, and S. Amar
A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha  gene expression: Molecular cloning, sequencing, characterization, and chromosomal assignment
PNAS, April 13, 1999; 96(8): 4518 - 4523.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.